AeroLEF®
AeroLEF® is a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain with first-in-class potential.
In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF, patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
The AeroLEF Concept:
Tailored, Flexible Dosing with Rapid Onset and Extended Duration of Analgesia
Click 'Play' to view flash animation. If video does not play, you may need to update Adobe Flash Player.
